News Releases

April 8, 2016

Replicel Life Sciences Applies to Amend Warrant Exercise Price and Extend Warrant Expiry Dates
VANCOUVER, BC – April 8, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”) (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine... Read full article

April 6, 2016

RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement
VANCOUVER, BC – April 6, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”) (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine... Read full article

February 26, 2016

RepliCel Life Sciences Inc. Announces Closing of Warrant Incentive Program
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – February 26, 2016 – RepliCel... Read full article

February 16, 2016

RepliCel Announces CEO Update
Milestones for 2016 include two clinical trial readouts, finalizing RCI-02 for a 2017 product launch, and initiation of Shiseido’s pattern baldness trial in Japan... Read full article

February 9, 2016

RepliCel Life Sciences Announces Warrant Exercise Incentive Program
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR... Read full article

January 11, 2016

RepliCel Receives European Patent for its Innovative Dermal Injector Technology
RCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic per procedure, and the enhanced treatment of fine wrinkles... Read full article

December 24, 2015

RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – December 23, 2015 – RepliCel... Read full article

December 17, 2015

RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin
Phase 1 clinical trial investigating the use of a patient-specific cell-based dermal rejuvenation product (RCS-01) is scheduled to deliver data in late 2016  VANCOUVER,... Read full article

December 16, 2015

RepliCel Life Sciences Announces Leadership Transition
Lee Buckler, former VP Business & Corporate Development, appointed CEO President & Director; David Hall retires as CEO and named Board Chairman VANCOUVER, BC... Read full article

November 23, 2015

RepliCel Life Sciences Inc. Announces Closing of First Tranche of Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – November 23, 2015 – RepliCel... Read full article